Literature DB >> 28533080

Influenza vaccination for patients with chronic obstructive pulmonary disease: Implications for pharmacists.

Rasha M Arabyat1, Dennis W Raisch2, Ludmila Bakhireva3.   

Abstract

BACKGROUND: Influenza virus is responsible for substantial morbidity and mortality. Specific populations are at higher risk for exacerbations from influenza virus, such as patients with chronic obstructive pulmonary disease (COPD). Influenza vaccination coverage among COPD patients is low. Pharmacists can improve influenza vaccination among COPD patients by recognizing factors that influence vaccination and addressing these factors.
OBJECTIVES: To (1) determine the recent influenza vaccination coverage among patients with COPD, (2) identify factors that were associated with immunization, and (3) interpret the results based upon Andersen's healthcare utilization model.
METHODS: The 2012 Behavioral Risk Factor Surveillance System (BRFSS) was accessed for the study. Among respondents age ≥ 25 years with COPD, presence of influenza vaccination was captured along with demographic, provider, insurance, and clinical variables. Weighted multiple logistic regression was used to identify significant factors associated with receiving influenza vaccination. The findings were interpreted according to predisposing, enabling, and need factors relevant to Anderson's model.
RESULTS: Influenza vaccination rate was 53% among COPD patients. Older age was a significant predisposing factor that increased vaccination (adjusted odds ratio [AOR] = 2.4; 95% CI:2.02-2.88). Predisposing factors that decreased vaccination were being Black or Hispanic (AOR = 0.72, 95% CI:0.59-0.86, and AOR = 0.78, 95% CI:0.61-0.98 respectively), and being a non smoker (former and never smokers had higher vaccination rates [AOR = 1.53, 95% CI = 1.3-1.72, and AOR = 1.36, 95% CI = 1.19-1.55 respectively]). Significant enabling factors included having health insurance (AOR = 1.68, 95% CI = 1.37-2.06), a primary physician (AOR = 1.63, 95% CI = 1.30-2.02), and the ability to see a physician regardless of cost (AOR = 1.33, 95% CI = 1.17-1.52). Significant need factors included the presence of comorbidities such as asthma (AOR = 1.18, 95% CI = 1.1-1.3), or diabetes (AOR = 1.36, 95% CI = 1.20-1.53), activity limitation (AOR = 1.16, 95% CI = 1.04-1.29), and having the last medical checkup within less than one year (AOR = 1.49, 95% CI = 1.31-1.70).
CONCLUSION: Influenza vaccination coverage among COPD patients is far below the Healthy People 2020 national goal. Several predisposing, enabling, and need factors influenced vaccination rate among COPD patients. Pharmacists can improve vaccination rate among COPD patients by recognizing these influencing factors and by acting as advocates, counselors, and administrators of influenza vaccine. Ultimately, with the collaborative efforts of other healthcare providers and public health initiatives, pharmacists can help achieve Healthy People 2020 objectives related to influenza vaccination.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Andersen's healthcare utilization model; Chronic obstructive pulmonary disorder (COPD); Enabling factors; Influenza vaccination; Need factors; Pharmacists; Predisposing factors

Mesh:

Substances:

Year:  2017        PMID: 28533080     DOI: 10.1016/j.sapharm.2017.02.010

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  6 in total

1.  Influenza and pneumonia vaccination rates in patients hospitalized with acute respiratory failure.

Authors:  Ipek Candemir; Sema Turk; Pinar Ergun; Dicle Kaymaz
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

2.  Pharmacists' Perspectives on Providing the Influenza Vaccine in Community Pharmacies: A Qualitative Study.

Authors:  Mohammad B Nusair; Rasha Arabyat; Tareq L Mukattash; Hamza Alhamad; Marah T Abu Ghaida; Mohammad Y Momani
Journal:  Risk Manag Healthc Policy       Date:  2020-10-16

3.  Risk factors associated with physical and mental distress in people who report a COPD diagnosis: latent class analysis of 2016 behavioral risk factor surveillance system data.

Authors:  Michael Stellefson; Samantha R Paige; Adam E Barry; Min Qi Wang; Avery Apperson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-04-10

4.  Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: a randomized controlled trial.

Authors:  Min Li; Guang-Chao Han; Yang Chen; Wen-Xiu Du; Fang Liu; Yu-Min Chi; Jun-Feng Du
Journal:  Braz J Med Biol Res       Date:  2020-11-27       Impact factor: 2.590

5.  Willingness to pay for COVID-19 vaccines in Jordan: Applying the health belief model.

Authors:  Rasha M Arabyat; Mohammad B Nusair; Sayer I Al-Azzam; Haneen A Amawi; Feras Darwish El-Hajji
Journal:  Res Social Adm Pharm       Date:  2022-09-13

Review 6.  Status of and strategies for improving adherence to COPD treatment.

Authors:  José Luis López-Campos; Esther Quintana Gallego; Laura Carrasco Hernández
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.